A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Dalantercept (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms The DASH Study
- Sponsors Acceleron Pharma
- 08 Jan 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.